Nothing Special   »   [go: up one dir, main page]

BR0211601A - Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos - Google Patents

Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos

Info

Publication number
BR0211601A
BR0211601A BR0211601-4A BR0211601A BR0211601A BR 0211601 A BR0211601 A BR 0211601A BR 0211601 A BR0211601 A BR 0211601A BR 0211601 A BR0211601 A BR 0211601A
Authority
BR
Brazil
Prior art keywords
preparing
technical process
flibanserine
stable polymorph
drug preparation
Prior art date
Application number
BR0211601-4A
Other languages
English (en)
Inventor
Carlo Bombarda
Enrica Dubini
Antoine Ezhaya
Original Assignee
Bidachem Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bidachem Spa filed Critical Bidachem Spa
Publication of BR0211601A publication Critical patent/BR0211601A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

"POLIMORFO ESTáVEL DE FLIBANSERINA, PROCESSO TéCNICO PARA A PREPARAçãO DO MESMO E O USO DO MESMO PARA A PREPARAçãO DE MEDICAMENTOS". A presente invenção refere-se ao polímero A da flibanserina (1), a um processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos.
BR0211601-4A 2001-08-02 2002-07-30 Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos BR0211601A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01118593 2001-08-02
EP01130180 2001-12-19
PCT/EP2002/008466 WO2003014079A1 (en) 2001-08-02 2002-07-30 Stable polymorph of flibanserin, technical process for its preparation and the use thereof for preparing medicaments

Publications (1)

Publication Number Publication Date
BR0211601A true BR0211601A (pt) 2004-08-24

Family

ID=26076670

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0211601-4A BR0211601A (pt) 2001-08-02 2002-07-30 Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos

Country Status (27)

Country Link
EP (2) EP1414816B1 (pt)
JP (1) JP3822601B2 (pt)
KR (1) KR100899297B1 (pt)
CN (1) CN1288147C (pt)
AR (2) AR036208A1 (pt)
AT (1) ATE288911T1 (pt)
AU (1) AU2002331361B2 (pt)
BR (1) BR0211601A (pt)
CA (1) CA2450093C (pt)
CO (1) CO5560572A2 (pt)
DE (1) DE60202958T2 (pt)
DK (1) DK1414816T3 (pt)
EA (1) EA006400B1 (pt)
ES (1) ES2237694T3 (pt)
HK (1) HK1070063A1 (pt)
HR (1) HRP20040107B1 (pt)
HU (1) HU228666B1 (pt)
IL (2) IL159151A0 (pt)
MX (1) MXPA04000913A (pt)
MY (1) MY127294A (pt)
NZ (1) NZ530510A (pt)
PL (1) PL210224B1 (pt)
PT (1) PT1414816E (pt)
RS (1) RS50742B (pt)
SI (1) SI1414816T1 (pt)
UA (1) UA76767C2 (pt)
WO (1) WO2003014079A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183410B2 (en) 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
DE10138273A1 (de) * 2001-08-10 2003-02-27 Boehringer Ingelheim Pharma Arzneimittel mit neuroprotektiver Wirkung
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
KR101054237B1 (ko) * 2002-05-22 2011-08-08 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 플리반세린 다형체 α를 함유하는 신규한 약제학적 조성물
WO2006119884A2 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
EP1991228A1 (en) * 2006-02-28 2008-11-19 Boehringer Ingelheim International GmbH Treatment of prevention of valvular heart disease with flibanserin
WO2007128802A2 (en) * 2006-05-09 2007-11-15 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of post-menopausal sexual desire disorders
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
KR20090042967A (ko) 2006-08-14 2009-05-04 베링거 인겔하임 인터내셔날 게엠베하 플리반세린 제형 및 이의 제조방법
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
BRPI0716436B8 (pt) 2006-08-25 2021-05-25 Boehringer Ingelheim Int sistema de liberação controlada e método para fabricação do mesmo
WO2008061966A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim International Gmbh New use of flibanserin
ATE524446T1 (de) 2006-12-20 2011-09-15 Boehringer Ingelheim Int Sulfatierte benzimidazolon-derivate mit gemischter serotonin-rezeptor-affinität
EP1955699A1 (en) * 2007-02-08 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Use of flibanserin for the treatment of insomnia
UY31335A1 (es) 2007-09-12 2009-04-30 Tratamiento de sintomas vasomotores
EP2090297A1 (en) 2008-02-13 2009-08-19 Boehringer Ingelheim International GmbH Formulations of flibanserin
CA2686480A1 (en) * 2008-12-15 2010-06-15 Boehringer Ingelheim International Gmbh New salts
CN104926734B (zh) * 2015-07-07 2017-04-05 苏州立新制药有限公司 氟班色林的制备方法
WO2017076356A1 (zh) * 2015-11-05 2017-05-11 苏州晶云药物科技有限公司 氟班色林的新晶型及其制备方法
CN113683570A (zh) * 2016-01-31 2021-11-23 孟晓明 氟班色林的新晶型及其制备方法及其用途
CN111303043A (zh) * 2019-04-19 2020-06-19 武汉万知化工医药有限公司 一种氟班色林盐酸盐的制备方法
CN115919860B (zh) * 2022-12-05 2023-11-10 中国药科大学 氟班色林在制备治疗雄激素脱发药物中的用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1251144B (it) * 1991-07-30 1995-05-04 Boehringer Ingelheim Italia Derivati del benzimidazolone

Also Published As

Publication number Publication date
CA2450093A1 (en) 2003-02-20
HUP0401201A3 (en) 2004-11-29
PL210224B1 (pl) 2011-12-30
MXPA04000913A (es) 2004-10-27
HK1070063A1 (en) 2005-06-10
JP3822601B2 (ja) 2006-09-20
ES2237694T3 (es) 2005-08-01
IL159151A (en) 2009-09-22
HRP20040107B1 (en) 2012-02-29
NZ530510A (en) 2004-07-30
YU7804A (sh) 2006-08-17
RS50742B (sr) 2010-08-31
PT1414816E (pt) 2005-04-29
AU2002331361B2 (en) 2008-06-05
ATE288911T1 (de) 2005-02-15
EA006400B1 (ru) 2005-12-29
EP1414816A1 (en) 2004-05-06
PL364598A1 (en) 2004-12-13
MY127294A (en) 2006-11-30
DE60202958D1 (de) 2005-03-17
EP1518858A1 (en) 2005-03-30
HRP20040107A2 (en) 2004-06-30
CO5560572A2 (es) 2005-09-30
CN1551879A (zh) 2004-12-01
WO2003014079A8 (en) 2003-11-20
AR036208A1 (es) 2004-08-18
EP1414816B1 (en) 2005-02-09
KR20040023704A (ko) 2004-03-18
CN1288147C (zh) 2006-12-06
HUP0401201A2 (hu) 2004-10-28
WO2003014079A1 (en) 2003-02-20
JP2004537597A (ja) 2004-12-16
EA200400252A1 (ru) 2004-08-26
DE60202958T2 (de) 2006-04-06
KR100899297B1 (ko) 2009-05-26
IL159151A0 (en) 2004-06-01
HU228666B1 (en) 2013-05-28
UA76767C2 (uk) 2006-09-15
CA2450093C (en) 2008-09-23
AR077416A2 (es) 2011-08-24
DK1414816T3 (da) 2005-04-11
SI1414816T1 (en) 2005-06-30

Similar Documents

Publication Publication Date Title
BR0211601A (pt) Polimorfo estável de flibanserina, processo técnico para a preparação do mesmo e o uso do mesmo para a preparação de medicamentos
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
BR0112589A (pt) Derivados de heteroarila e sua aplicação como medicamento
BR0007980A (pt) Processo para a preparação de derivadosmulti-reticulados de ácido hialurÈnico, hamulti-reticulado, ha reticulado em si próprio,produto, e, uso de ha
BR0214469A (pt) 17alfa-alquil-17beta-óxi-estratrienos e produtos intermediários para sua preparação, aplicação dos 17alfa-alquil-17beta-óxi-estratrienos para a preparação de medicamentos bem como preparações farmacêuticas
SE9904505D0 (sv) Novel compounds
BR0014827A (pt) Derivados de terc-butil-(7-metil-imidazo (1,2-a) piridin-3-il) amina, procedimento de sua preparação, medicamentos que os contém, sua utilização para a preparação de medicamento para inibição de no-sintase e composições farmacêuticas que os contém
BR0015048A (pt) Sal farmacêutico, medicamento, uso de pelo menos um sal de tramadol e formas de apresentação
BR0215312A (pt) Uso de um composto, método para inibir a aurora quinase em um animal de sangue quente, composto, composição farmacêutica, e, processo para a preparação de um composto
DE60115029D1 (de) Pharmazeutische zusammensetzungen enthaltend cannabidiol-derivate
BR0214243A (pt) Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida
NO20035450D0 (no) Antranilsyreamider med en heteroarylsulfonyl sidekjede, fremgangsmåte for fremstilling derav, anvendelse som et legemiddel eller diagnostiske-og farmas degree ytiske preparater som inneholder nevnte forbindelser
MY123193A (en) Novel 2-(iminomethyl)amino-phenyl derivatives,preparation,application as medicines and compositions containing same
BR0208468A (pt) Camsilato de amlodipina e processo para sua preparação
BR0312728A (pt) Formulação em tablete dispersìvel e processo para sua preparação
BRPI0607614A2 (pt) sal de besilato da 7-(2-(4-3-trifluorometil-fenil)-1,2,3,6-tetrahidropirid- 1-il)etil) isoquinoleìna, o respectivo medicamento, composição farmacêutica e uso
BR0211198A (pt) Composições farmacêuticas e seu uso
PT1165081E (pt) Processo para a preparacao de preparacoes farmaceuticas cintendo tolperisona, para administracao oral
BR0211063A (pt) Sais de derivados anticonvulsivantes
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
BR0112807A (pt) Derivados de indol e sua aplicação como medicamento
ES2191449T3 (es) Derivados de ciclopentabenzofurano y su uso.
BRPI0416188A (pt) formulações de medicamentos que contêm aromatizante, com propriedades farmacêuticas aperfeiçoadas
ATE286894T1 (de) 2h-1-benzopyran-derivate, prozesse zu ihrer herstellung und pharmazeutische zusammensetzungen
BR9705143A (pt) Derivados de 10,13,15-trioxatriciclo [9.2.1.1(9.6)] -pentadecanona, processo para a sua preparação e medicamentos que contém estes compostos

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25A Requested transfer of rights approved

Owner name: SPROUT PHARMACEUTICALS, INC. (US)

B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.